MedMira Files Patent Application for Next Generation Rapid Test
MedMira Inc. announced that it has filed a patent application with the United States Patent Office for its new rapid test platform. MedMira's research & development team has been working on a next generation, rapid test based on the company's patented flow-through diagnostic technology. This next generation rapid test is built on the key quality and performance attributes that have enabled MedMira's rapid HIV and HIV/Hepatitis combination tests to obtain regulatory approvals from the most stringent regulatory authorities in the world, including United States, Canada, China, India, Russia, and Europe.
"Our new test platform provides the user with an even simpler, user-friendly testing procedure than we currently offer in our rapid tests, without sacrificing the high quality and consistent performance that MedMira has built its reputation on," said Dr. Neeraj Vats, Vice President of Technology & Intellectual Property, MedMira Inc. "The new test platform makes it possible to perform a rapid, flow-through test in just two easy steps."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.